First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis

Clinical Breast Cancer ◽

10.1016/j.clbc.2021.01.019 ◽

2021 ◽

Author(s):

Xiaoting Huang ◽

Shen Lin ◽

Xin Rao ◽

Dayong Zeng ◽

Hang Wang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Premenopausal Women ◽

Line Treatment ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer

European Journal of Cancer Care ◽

10.1111/ecc.12733 ◽

2017 ◽

Vol 26 (6) ◽

pp. e12733 ◽

Author(s):

H. Ding ◽

L. Fang ◽

W. Xin ◽

Y. Tong ◽

Q. Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

RE: “Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer,” by Ding H., et al.

European Journal of Cancer Care ◽

10.1111/ecc.12834 ◽

2018 ◽

Vol 27 (2) ◽

pp. e12834

Author(s):

Claire Telford

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis

Targeted Oncology ◽

10.1007/s11523-019-00633-9 ◽

2019 ◽

Vol 14 (2) ◽

pp. 139-148 ◽

Author(s):

Qianqian Guo ◽

Xiaojie Lin ◽

Lingling Ye ◽

Rui Xu ◽

Yan Dai ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Meta Analysis ◽

Line Treatment ◽

Comparative Efficacy ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-013-2495-0 ◽

2013 ◽

Vol 138 (3) ◽

pp. 961-965 ◽

Author(s):

Pui San Tan ◽

Benjamin Haaland ◽

Alberto J. Montero ◽

Gilberto Lopes

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Meta Analysis ◽

Advanced Breast ◽

Line Treatment ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

P1-16-01: A Randomized, Double-Blinded, Controlled Study of Exemestane vs. Anastrozole for the First-Line Treatment of Postmenopausal Japanese Women with Hormone Receptor Positive Advanced Breast Cancer.

10.1158/0008-5472.sabcs11-p1-16-01 ◽

2011 ◽

Author(s):

N Masuda ◽

H Iwata ◽

S Ohno ◽

Y Rai ◽

Y Sato ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Japanese Women ◽

Controlled Study ◽

Line Treatment ◽

Hormone Receptor Positive ◽

Double Blinded ◽

First Line Treatment

Download Full-text

Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor–positive/HER2-negative advanced breast cancer women with or without visceral disease

Anti-Cancer Drugs ◽

10.1097/cad.0000000000000904 ◽

2020 ◽

Vol 31 (5) ◽

pp. 528-532

Author(s):

Olga Nigro ◽

Cristina Marrazzo ◽

Elisa Gallerani ◽

Linda Bascialla ◽

Rossana Gueli ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Kinase Inhibitors ◽

Line Treatment ◽

Cyclin Dependent Kinase ◽

Hormone Receptor Positive ◽

Visceral Disease ◽

First Line Treatment

Download Full-text

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-013-2573-3 ◽

2013 ◽

Vol 139 (2) ◽

pp. 441-451 ◽

Author(s):

Hiroji Iwata ◽

Norikazu Masuda ◽

Shinji Ohno ◽

Yoshiaki Rai ◽

Yasuyuki Sato ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Japanese Women ◽

Controlled Study ◽

Line Treatment ◽

Double Blind ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

Anastrozole is as effective as tamoxifen as first-line treatment for hormone receptor positive advanced breast cancer

Evidence-based Oncology ◽

10.1054/ebon.2002.0044 ◽

2002 ◽

Vol 3 (4) ◽

pp. 177-178

Author(s):

Kathy D Miller

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Line Treatment ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

158TiP BioItaLEE: Molecular features of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) PIK3CA-mutated advanced breast cancer (ABC) on first-line treatment with ribociclib + letrozole and on second-line treatment with alpelisib + fulvestrant

Annals of Oncology ◽

10.1016/j.annonc.2020.08.279 ◽

2020 ◽

Vol 31 ◽

pp. S302

Author(s):

G. Allegrini ◽

M. Orditura ◽

L. Del Mastro ◽

C. Zamagni ◽

R. Torrisi ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Line Treatment ◽

Second Line ◽

Molecular Features ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.

10.1158/0008-5472.sabcs11-p1-17-01 ◽

2011 ◽

Author(s):

PD Ryan ◽

P Neven ◽

KL Blackwell ◽

LY Dirix ◽

CH Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Line Treatment ◽

Hormone Receptor Positive ◽

Open Label Phase ◽

First Line Treatment

Download Full-text